-
公开(公告)号：US20250032501A1
公开(公告)日：2025-01-30
申请号：US18580831
申请日：2022-07-21
Applicant: Memorial Sloan-Kettering Cancer Center , Memorial Hospital for Cancer and Allied Diseases , Sloan-Kettering Institute for Cancer Research
Inventor： Frederic Geissmann , Rocio Vicario
IPC: A61K31/5377 , A61K31/166 , A61K31/18 , A61K31/365 , A61K31/404 , A61K31/4184 , A61K31/437 , A61K31/44 , A61K31/4412 , A61K31/4418 , A61K31/4439 , A61K31/4523 , A61K31/4709 , A61K31/496 , A61K31/505 , A61K31/506 , A61K31/517 , A61K31/519 , A61P25/28
Abstract: The present technology relates to methods for treating, preventing, and/or ameliorating Alzheimer's disease, in a subject in need thereof. In particular aspects, the present technology relates to the use of MAPK inhibitors to treat, prevent, and/or ameliorate Alzheimer's disease.
-
公开(公告)号：US20240423951A1
公开(公告)日：2024-12-26
申请号：US18824504
申请日：2024-09-04
Inventor： Mark G. Frattini , Hakim Djaballah , Thomas J. Kelly
IPC: A61K31/365 , A61K9/00 , A61K31/122 , A61K31/352 , A61N5/10 , C07D493/08 , C07D493/18 , C09B13/02 , C09B61/00 , C12Q1/6886
Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
-
公开(公告)号：US20240319174A1
公开(公告)日：2024-09-26
申请号：US18732216
申请日：2024-06-03
Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
Inventor： Karuna Ganesh
IPC: G01N33/50 , C12N1/20 , C12N5/0783 , C12N5/09 , C12Q1/02
CPC classification number: G01N33/5088 , C12N1/20 , C12N5/0636 , C12N5/0693 , C12Q1/025 , C12N2501/11 , C12N2501/415 , C12N2501/998 , C12N2503/02
Abstract: The present disclosure provides organoid co-cultures and methods of using such co-cultures. In particular, the present disclosure provides organoid-immune cell and organoid-bacterial cell co-cultures. The present disclosure further provides methods for testing therapeutic agents using the disclosed organoid co-cultures.
-
公开(公告)号：US20240309457A1
公开(公告)日：2024-09-19
申请号：US18273715
申请日：2022-01-21
Applicant: THE BROAD INSTITUTE, INC. , MEMORIAL SLOAN-KETTERING CANCER CENTER , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , MEMORIAL HOSPITAL FOR THE TREATMENT OF CANCER AND ALLIED DISEASES , GENOME RESEARCH LIMITED
Inventor： Mia Petljak , Michael R. Stratton , John Maciejowski
IPC: C12Q1/6886 , C07K16/40 , C12N5/09 , C12N15/113 , G01N33/50
CPC classification number: C12Q1/6886 , C07K16/40 , C12N5/0693 , C12N15/1137 , G01N33/5011 , C12N2310/14 , C12N2510/00 , C12Q2600/106 , C12Q2600/156
Abstract: The present disclosure provides methods for treating cancer in a subject (by inhibiting e.g., APOBEC3A, APOBEC3B, or REV1), and methods of diagnosing cancer in a subject. Methods of tracking mutagenesis induced by a gene of interest (e.g., APOBEC3A, APOBEC3B, or REV1) and methods of screening for inhibitors and synthetic lethalities are also described herein. Further provided by the present disclosure are cell lines and antibodies for use in the methods described herein.
-
公开(公告)号：US20240262910A1
公开(公告)日：2024-08-08
申请号：US18592427
申请日：2024-02-29
Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES , TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.
Inventor： Anthony Daniyan , Renier J. BRENTJENS , Ivo C. LORENZ , Abdul KHAN
CPC classification number: C07K16/2803 , A61K47/6849 , G01N33/58 , G01N33/6854 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/92 , G01N2333/70596
Abstract: The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to CD33 and methods of using such antibodies or antigen-binding fragments thereof same.
-
公开(公告)号：US20240252640A1
公开(公告)日：2024-08-01
申请号：US18591403
申请日：2024-02-29
Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
Inventor： Janneke E. Jaspers , Marjan ZAMAN , Renier J. BRENTJENS
IPC: A61K39/00 , A61P35/00 , C07K14/705 , C07K14/725 , C07K16/18 , C12N5/0783
CPC classification number: A61K39/4631 , A61K39/4611 , A61K39/4643 , A61P35/00 , C07K14/7051 , C07K14/70521 , C07K16/18 , C12N5/0636 , A61K2039/572 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C12N2510/00
Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target DLL3 and cells comprising such DLL3-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the DLL3-targeted antigen-recognizing receptors for treatment.
-
公开(公告)号：US20240219403A1
公开(公告)日：2024-07-04
申请号：US18554176
申请日：2022-04-08
Applicant: Memorial Sloan-Kettering Cancer Center , Memorial Hospital for Cancer and Allied Diseases , Sloan-Kettering Institute for Cancer Research
Inventor： Piro LITO
IPC: G01N33/68 , A61K45/06 , C12Q1/6886
CPC classification number: G01N33/6893 , A61K45/06 , C12Q1/6886 , G01N33/6854 , C12Q2600/158 , G01N2800/52
Abstract: The present disclosure relates to methods for determining whether a cancer patient harboring a constitutively active KRAS mutation will be responsive to treatment with a KRASG12C inhibitor that selectively targets the inactive state of KRAS. These methods are based on assaying regulators of G-protein signaling (RGS) expression in the cancer patient.
-
公开(公告)号：US20240209353A1
公开(公告)日：2024-06-27
申请号：US18285925
申请日：2022-04-07
Applicant: Memorial Sloan-Kettering Cancer Center , Memorial Hospital for Cancer and Allied Diseases , Sloan-Kettering Institute for Cancer Research
Inventor： Craig B. Thompson , Simon Schwoerer , Jiajun Zhu
CPC classification number: C12N15/11 , C12N9/22 , C12N2310/20 , C12N2800/80
Abstract: Aspects of the disclosure provide methods for inhibiting cell proliferation and protein synthesis utilizing an antagonist of nicotinamide adenine dinucleotide kinase 2 (NADK2). In some aspects, these methods are used to treat a disease such as cancer or a disorder such as a fibrotic disorder. Further provided herein are compositions comprising a nutrient-deficient cell culture medium and an antagonist of NADK2.
-
公开(公告)号：US20230346938A1
公开(公告)日：2023-11-02
申请号：US18049151
申请日：2022-10-24
Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES , MILLENNIUM PHARMACEUTICALS, INC.
Inventor： Judith FEUCHT , Jorge MANSILLA-SOTO , Isabelle RIVIERE , Michel SADELAIN , Loic VINCENT , Gary SHAPIRO , Mei Rosa NG , Dan TAVARES , Xingyue HE
IPC: A61K39/00 , C07K16/28 , C07K14/725 , C07K14/705 , A61P35/00
CPC classification number: A61K39/4631 , C07K16/2803 , C07K14/7051 , C07K14/70521 , A61K39/4611 , A61K39/4613 , A61K39/4632 , A61K39/464412 , A61P35/00 , C07K2317/622 , A61K2239/48
Abstract: The presently disclosed subject matter provides chimeric antigen receptors (CARs) that specifically target CD19 and cells comprising such CD19-targeted CARs. The presently disclosed subject matter further provides uses of the CD19-targeted CARs for treatment, e.g., for treating blood cancer.
-
公开(公告)号：US20230158180A1
公开(公告)日：2023-05-25
申请号：US17857413
申请日：2022-07-05
Inventor： Michelle S. Bradbury , Ulrich Wiesner , Oula Penate Medina , Andrew Burns , Jason S. Lewis , Steven M. Larson
IPC: A61K51/12 , G01N33/574 , G01N33/543 , G01N33/552 , G01N33/58 , G01N33/60 , A61K49/00
CPC classification number: A61K51/1244 , G01N33/574 , G01N33/54346 , G01N33/552 , G01N33/582 , G01N33/587 , G01N33/60 , A61K49/0093 , A61K49/0002
Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.
